# EDGAR Filing Document

**Accession Number:** 0002071581
**File Stem:** 0001127602-25-017051
**Filing Date:** 2025-6
**Character Count:** 6235
**Document Hash:** df3a12ea9db056d2234963785e4b3914
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001127602-25-017051.hdr.sgml**: 20250609

**ACCESSION NUMBER**: 0001127602-25-017051

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250601

**FILED AS OF DATE**: 20250609

**DATE AS OF CHANGE**: 20250609

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Gopinathan Suma
- **CENTRAL INDEX KEY:** 0002071581

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-30111
- **FILM NUMBER:** 251033036

**MAIL ADDRESS:**
- **STREET 1:** 2445 TECHNOLOGY FOREST BLVD
- **STREET 2:** 11TH FLOOR
- **CITY:** SPRING
- **STATE:** TX
- **ZIP:** 77381
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** LEXICON PHARMACEUTICALS, INC.
- **CENTRAL INDEX KEY:** 0001062822
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 760474169
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 2445 TECHNOLOGY FOREST BLVD.
- **STREET 2:** SUITE 1100
- **CITY:** THE WOODLANDS
- **STATE:** TX
- **ZIP:** 77381
- **BUSINESS PHONE:** 2818633000

**MAIL ADDRESS:**
- **STREET 1:** 2445 TECHNOLOGY FOREST BLVD.
- **STREET 2:** SUITE 1100
- **CITY:** THE WOODLANDS
- **STATE:** TX
- **ZIP:** 77381

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** LEXICON PHARMACEUTICALS, INC./DE
- **DATE OF NAME CHANGE:** 20070426

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** LEXICON GENETICS INC/TX
- **DATE OF NAME CHANGE:** 20000126

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Gopinathan Suma<br><sub>(Last) (First) (Middle)</sub><br>2445 TECHNOLOGY FOREST BLVD<br>11TH FLOOR<br><sub>(Street)</sub><br>THE WOODLANDS, TX 77381<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>LEXICON PHARMACEUTICALS, INC. [ LXRX ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2025-06-01 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_SVP, Discovery_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Common Stock | 74520 | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Stock Option (Right to Buy) | <sup>(1)</sup> | 2027-02-09 | Common Stock | 480 | $14.44 | D |  |
| Stock Option (Right to Buy) | <sup>(1)</sup> | 2028-02-08 | Common Stock | 1000 | $9.79 | D |  |
| Stock Option (Right to Buy) | <sup>(1)</sup> | 2029-02-07 | Common Stock | 2000 | $5.16 | D |  |
| Stock Option (Right to Buy) | <sup>(1)</sup> | 2030-02-06 | Common Stock | 4800 | $3.31 | D |  |
| Stock Option (Right to Buy) | <sup>(1)</sup> | 2031-02-11 | Common Stock | 4000 | $8.38 | D |  |
| Stock Option (Right to Buy) | <sup>(1)</sup> | 2032-02-10 | Common Stock | 10000 | $3.20 | D |  |
| Restricted Stock Units | <sup>(2)</sup> | <sup>(2)</sup> | Common Stock | 14000 | <sup>(3)</sup> | D |  |
| Stock Option (Right to Buy) | <sup>(1)</sup> | 2033-02-09 | Common Stock | 28000 | $2.43 | D |  |
| Restricted Stock Units | <sup>(2)</sup> | <sup>(2)</sup> | Common Stock | 40620 | <sup>(3)</sup> | D |  |
| Stock Option (Right to Buy) | <sup>(1)</sup> | 2034-02-08 | Common Stock | 60930 | $2.15 | D |  |
| Restricted Stock Units | <sup>(2)</sup> | <sup>(2)</sup> | Common Stock | 196920 | <sup>(3)</sup> | D |  |
| Stock Option (Right to Buy) | <sup>(1)</sup> | 2035-02-13 | Common Stock | 196920 | $0.695 | D |  |
| Stock Option (Right to Buy) | <sup>(1)</sup> | 2026-02-28 | Common Stock | 3790 | $9.07 | D |  |

---

### Footnotes:

(1) Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter.

(2) Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant.

(3) Each restricted stock unit represents a contingent right to receive one share of common stock.

**Signature:** /s/ Suma Gopinathan, M.S, Ph.D.  
**Date:** 2025-06-09

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**